DDIT3 and diffuse large B-cell lymphoma: Activation of this pathway was related to poor treatment response and decreased survival time in DLBCL patients treated with CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) but not in those treated with rituximab-CHOP (R-CHOP)[44].